Meeting Report
Published on 25 March 2025
Biosimilar Red Tape Elimination Act (S.2305): weakening FDA regulatory standards for biosimilars, undermining physician confidence and jeopardizing patient health
Author(s): Michael S Reilly, Esq, Ralph D McKibbin, MD, FACP, FACG, AGAF, Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP, Andrew Spiegel, Esq
interchangeable biosimilar, misinformation, switch studies
DOI: 10.5639/gabij.2025.1401.005
633 views
Letters to the Editor
Meeting Report
Letters to the Editor
Interview
Editor's Letter
Editor's Letter